Development of 131I-tositumomab.

  title={Development of 131I-tositumomab.},
  author={Valerie J. Lewington},
  journal={Seminars in oncology},
  volume={32 1 Suppl 1},
The median survival for patients with advanced indolent non-Hodgkin's lymphoma (NHL) has remained at 7 to 8 years since the 1960s. Targeted treatment using radioimmunotherapy (RIT), radiolabeled monoclonal antibodies directed against tumor-specific antigens, is an attractive option for this patient population, combining the advantages of an active biologic therapy with low dose-rate irradiation of an inherently radiosensitive tumor. Two anti-CD20 RIT agents have now been approved for the… CONTINUE READING